Phase II study of sorafenib and bortezomib for first-line treatment of metastatic or unresectable renal cell carcinoma

Arpit Rao, Richard Lauer

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of sorafenib and bortezomib for first-line treatment of metastatic or unresectable renal cell carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences